[1]
|
Kusamura, S., Kepenekian, V., Villeneuve, L., et al. (2021) Peritoneal Mesothelioma: PSOGI/EURACAN Clinical Prac-tice Guidelines for Diagnosis, Treatment and Follow-Up. European Journal of Surgical Oncology, 47, 36-59.
https://doi.org/10.1016/j.ejso.2020.02.011
|
[2]
|
Kaya, H., Sezgı, C., Tanrıkulu, A.C., et al. (2014) Prognostic Fac-tors Influencing Survival in 35 Patients with Malignant Peritoneal Mesothelioma. Neoplasma, 61, 433-438. https://doi.org/10.4149/neo_2014_053
|
[3]
|
Yan, T.D., Hassan, R., Welch, L. and Sugarbaker, P.H. (2007) Ad-vances in Diffuse Malignant Peritoneal Mesothelioma. Oncology Reviews, 1, 53-64. https://doi.org/10.1007/s12156-007-0007-3
|
[4]
|
Salo, S.A.S., Lantto, E., Robinson, E., Myllärniemi, M., Laak-sonen, S., Salo, J.A., Rantanen, T. and Ilonen, I. (2020) Prognostic Role of Radiological Peritoneal Cancer Index in Ma-lignant Peritoneal Mesothelioma: National Cohort Study. Scientific Reports, 10, Article No. 13257. https://doi.org/10.1038/s41598-020-70044-8
|
[5]
|
Carbone, M., Adusumilli, P.S., Alexander, H.R., et al. (2019) Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy. CA: A Cancer Journal for Clinicians, 69, 402-429. https://doi.org/10.3322/caac.21572
|
[6]
|
曾艳, 童瑞, 王翔耀, 等. 恶性腹膜间皮瘤26例临床特点及预后影响因素分析[J]. 解放军医学院学报, 2015, 36(6): 559-562, 567.
|
[7]
|
中国抗癌协会腹膜肿瘤专业委员会, 中国抗癌协会肿瘤热疗专业委员会, 北京癌症防治学会肿瘤热疗专业委员会. 弥漫性恶性腹膜间皮瘤诊治中国专家共识[J]. 中华医学杂志, 2021, 101(36): 2839-2849.
|
[8]
|
Baratti, D., Kusamura, S. and Deraco, M. (2009) Cir-culating CA125 and Diffuse Malignant Peritoneal Mesothelioma. European Journal of Surgical Oncology, 35, 1198-1199. https://doi.org/10.1016/j.ejso.2009.04.007
|
[9]
|
Bruno, F., Baratti, D., Martinetti, A., Morelli, D., Sot-totetti, E., Bonini, C., Guaglio, M., Kusamura, S. and Deraco, M. (2018) Mesothelin and Osteopontin as Circulating Markers of Diffuse Malignant Peritoneal Mesothelioma: A Preliminary Study. European Journal of Surgical Oncology, 44, 792-798. https://doi.org/10.1016/j.ejso.2018.02.010
|
[10]
|
Marchevsky, A.M. (2008) Application of Immuno-histochemistry to the Diagnosis of Malignant Mesothelioma. Archives of Pathology & Laboratory Medicine, 132, 397-401. https://doi.org/10.5858/2008-132-397-AOITTD
|
[11]
|
杜雪梅, 昌红, 李雁. 恶性腹膜间皮瘤临床病理进展[J]. 临床与实验病理学杂志, 2021, 37(4): 441-445.
|
[12]
|
Tohumcuoglu, M., Büyüksimsek, M., Kara, I.O., et al. (2019) The Prognostic Analysis of the Some Clinicopathological Parameters and Gene Protein Expressions in Malignant Mesothelioma. Tüberküloz ve Toraks, 67, 162-168.
https://doi.org/10.5578/tt.68517
|
[13]
|
Manzini, V.P., Recchia, L., Cafferata, M., et al. (2010) Malignant Peritoneal Mesothelioma: A Multicenter Study on 81 Cases. Annals of Oncology, 1, 348-353. https://doi.org/10.1093/annonc/mdp307
|
[14]
|
Sauter, J.L., Dacic, S., Galateau-Salle, F., et al. (2022) The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. Journal of Thoracic Oncology, 7, 608-622.
https://doi.org/10.1016/j.jtho.2021.12.014
|
[15]
|
Liu, S., Staats, P., Lee, M., et al. (2014) Diffuse Mesothelioma of the Peritoneum: Correlation between Histological and Clinical Parameters and Survival in 73 Patients. Pathology, 46, 604-609.
https://doi.org/10.1097/PAT.0000000000000181
|
[16]
|
Baratti, D., Kusamura, S., Cabras, A.D. and Deraco, M. (2012) Cytoreductive Surgery with Selective versus Complete Parietal Peritonectomy Followed by Hyperthermic Intra-peritoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. Annals of Surgical Oncology, 19, 1416-1424.
https://doi.org/10.1245/s10434-012-2237-2
|
[17]
|
Boussiosa, S., Moschettab, M., Karathanasia, A., et al. (2018) Malignant Peritoneal Mesothelioma: Clinical Aspects, and Therapeutic Perspectives. Annals of Gastroenterology, 31, 1-11. https://doi.org/10.20524/aog.2018.0305
|
[18]
|
Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., et al. (2003) Phase Ⅲ Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 21, 2636-2644. https://doi.org/10.1200/JCO.2003.11.136
|
[19]
|
江路, 杨乐, 杨子萱, 等. 3例恶性腹膜间皮瘤的临床表现和基因突变特点分析及文献回顾[J]. 现代肿瘤医学, 2022, 30(13): 2415-2419.
|
[20]
|
Schaub, N.P., Alimchandani, M., Quezado, M., et al. (2013) A Novel Nomogram for Perito-neal Mesothelioma Predicts Survival. Annals of Surgical Oncology, 20, 555-561. https://doi.org/10.1245/s10434-012-2651-5
|
[21]
|
Helm, J.H., Miura, J.T., Glenn, J.A., et al. (2015) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 22, 1686-1693. https://doi.org/10.1245/s10434-014-3978-x
|
[22]
|
杜雪梅, 李鑫宝, 孟巍, 等. 恶性腹膜间皮瘤100例临床病理特征及预后分析[J]. 中国肿瘤临床, 2023, 50(8): 403-410.
|